Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Abudoureyimu, Mubalake; Lai, Yongting; Tian, Chen; Wang, Ting; Wang, Rui; Chen, Xiaoyuan

doi:10.3389/fonc.2019.01182

Cited by 39 publications

(31 citation statements)

References 104 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different species of Ads have various receptors to infect the target cell. Coxsackievirus-Ad receptor (CAR) is known as the main receptor of Ads, while CD46, CD80, CD86, and desmoglein-2 (DSG2) are other receptors for Ads [ 43 ]. Ads require two interactions to infect target cells: (1) binding the fiber knob of the virus to the cell surface receptor and (2) binding the arginine-glycine-aspartic acid (RGD) motif in the penton base of Ads to target cells integrin, specifically αvß3 [ 44 ].…”

Section: Oncolytic Virotherapymentioning

confidence: 99%

A review on the advances and challenges of immunotherapy for head and neck cancer

et al. 2021

View full text Add to dashboard Cite

Head and neck cancer (HNC), which includes lip and oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx malignancies, is one of the most common cancers worldwide. Due to the interaction of tumor cells with immune cells in the tumor microenvironment, immunotherapy of HNCs, along with traditional treatments such as chemotherapy, radiotherapy, and surgery, has attracted much attention. Four main immunotherapy strategies in HNCs have been developed, including oncolytic viruses, monoclonal antibodies, chimeric antigen receptor T cells (CAR-T cells), and therapeutic vaccines. Oncorine (H101), an approved oncolytic adenovirus in China, is the pioneer of immunotherapy for the treatment of HNCs. Pembrolizumab and nivolumab are mAbs against PD-L1 that have been approved for recurrent and metastatic HNC patients. To date, several clinical trials using immunotherapy agents and their combination are under investigation. In this review, we summarize current the interaction of tumor cells with immune cells in the tumor microenvironment of HNCs, the main strategies that have been applied for immunotherapy of HNCs, obstacles that hinder the success of immunotherapies in patients with HNCs, as well as solutions for overcoming the challenges to enhance the response of HNCs to immunotherapies.

show abstract

Section: Oncolytic Virotherapymentioning

confidence: 99%

A review on the advances and challenges of immunotherapy for head and neck cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…They can elicit strong immune effects and are generally used in oncolytic therapy. 3 Lentiviral vectors are single-stranded RNA viruses that can efficiently accommodate 10 kb of a transgene. 4 They integrate their genetic material into the host genome, allowing long-term expression of the therapeutic gene.…”

Section: Treatment Effectmentioning

confidence: 99%

Gene therapies targeting the liver

Cozmescu

Counsell

Gissen

2021

Journal of Hepatology

View full text Add to dashboard Cite

“…The use of dendritic cells, an important platform for T cell activation, as vaccines has also demonstrated interesting results in several studies Table 3. [68][69][70][71][72][73][74] Some other teams focused on the use of oncolytic viruses 75 with results to be demonstrated in clinical trials in the future. Cold-inducible RNA binding protein 73 or Tumor RNA-Loaded Lipid Nanoparticles 74 have also recently been study and demonstrated potential, especially in use with ICI.…”

Section: Dovepress 1041mentioning

confidence: 99%

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances

Charneau

Suzuki

Shimomura

et al. 2021

JHC

View full text Add to dashboard Cite

Primary liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. After surgery, up to 70% of patients experience relapses. The current first-line therapy for advanced cases of hepatocellular carcinoma (HCC) comprises sorafenib and lenvatinib administered as single-drug therapies. Regorafenib, cabozantinib, and ramucirumab are administered as second-line therapies. Recently, it has been reported that using the immune checkpoint inhibitors atezolizumab (anti-PDL1 antibody) and bevacizumab (anti-VEGF antibody) leads to longer overall survival of unresectable cases, when compared with the use of sorafenib. The role of cancer immunity against HCC has attracted the attention of clinicians. In this review, we describe our phase I/II clinical trials of peptide vaccines targeting GPC3 in HCC and discuss the potential of peptide vaccines targeting common cancer antigens that are highly expressed in HCC, such as WT-I, AFP, ROBO1, and FOXM1. Further, we introduce recent cancer vaccines targeting neoantigens, which have attracted attention in recent times, as well as present our preclinical studies, the results of which might aid to initiate a neoantigen vaccine clinical trial, which would be the first of its kind in Japan.

show abstract

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Cited by 39 publications

References 104 publications

A review on the advances and challenges of immunotherapy for head and neck cancer

A review on the advances and challenges of immunotherapy for head and neck cancer

Gene therapies targeting the liver

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances

Contact Info

Product

Resources

About